Clinical Trials Logo

Colorectal Neoplasms clinical trials

View clinical trials related to Colorectal Neoplasms.

Filter by:

NCT ID: NCT03727763 Recruiting - Colorectal Cancer Clinical Trials

Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)

Start date: October 8, 2018
Phase: Phase 2
Study type: Interventional

This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.

NCT ID: NCT03725254 Recruiting - Colorectal Cancer Clinical Trials

CRT Versus Surgery for Retroperitoneal or Paraaortic Lymph Node Recurrence of CRC

Start date: October 20, 2018
Phase: Phase 2
Study type: Interventional

The study aims to compare the effects of chemoradiation versus radical surgery in treating retro-peritoneal or para-aortic lymph node metastasis in colorectal cancer. By prolonging patients' progression-free survival, local control rate and overall survival, investigators can conclude the best regimen for colorectal cancer patients.

NCT ID: NCT03711240 Recruiting - Colorectal Cancer Clinical Trials

The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases

CBL
Start date: January 8, 2019
Phase: Phase 2
Study type: Interventional

This single-arm study will evaluate the resection rate of liver metastases in patients with metastatic colorectal cancer and borderline unresectable liver metastases receiving treatment with bevacizumab in combination with modified-FOLFOXIRI as first line treatment. Patients will receive bevacizumab (5 mg/kg) plus modified-FOLFOXIRI (irinotecan 150 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil 2400 mg/m2 as a 46-h continuous infusion) every 14 days as neoadjuvant chemotherapy regimen. This study treatment will continue until surgery, disease progression, unacceptable toxicity, or patient refusal.

NCT ID: NCT03705442 Recruiting - Clinical trials for Colorectal Cancer Metastatic

Probiotics as Adjuvant Therapy in the Treatment of Metastatic Colorectal Cancer

Probat-tmcc-17
Start date: February 9, 2018
Phase: Phase 2
Study type: Interventional

The research will be prospective, randomised, placebo controlled and double-blinded.The research will be carried on with regards to Helsinki Declaration and following the guidelines of Good Clinical Practice.

NCT ID: NCT03694080 Recruiting - Colorectal Cancer Clinical Trials

Calcium Electroporation for Early Colorectal Cancer

Start date: November 1, 2018
Phase: Phase 1
Study type: Interventional

This is an explorative, phase I clinical trial. The aim of this study is to establish the safety and efficacy of treating patients with early colorectal cancer with calcium electroporation prior to intended curative surgery.

NCT ID: NCT03692429 Recruiting - Clinical trials for Unresectable Metastatic Colorectal Cancer

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

alloSHRINK
Start date: November 28, 2018
Phase: Phase 1
Study type: Interventional

The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy

NCT ID: NCT03686254 Recruiting - Clinical trials for Colorectal Neoplasms Malignant

The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM

Start date: July 16, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Basing on the strong evidence from former researches, patients with CRLM can benefit from the treatment of bevacizumab combined with sencond-line chemotherapy. Recently, although with the popularization of RFA, the role that RFA plays in the long term survival of patients with metastatic colorectal cancer (CRC) is still confused. In this designed, randomized, controlled, prospective, and open clinical trial, the effectiveness of RFA combined with second-line chemotherapy + bevacizumab on unresectable CRLM is going to be evaluated compared with that of second-line chemotherapy + bevacizumab. After screened by inclusion and exclusion criteria, the eligible subjects will be randomly allocated into the experimental group-with the treatment of RFA + second-line chemotherapy + bevacizumab and control group-with the treatment of second-line chemotherapy + bevacizumab equally.

NCT ID: NCT03679039 Recruiting - Clinical trials for Colorectal Cancer With Liver Metastases

A Model for Predicting the Efficacy of Conversion Therapy for Patients With Colorectal Cancer Liver Metastases by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA

Start date: September 20, 2018
Phase:
Study type: Observational

In this study, the investigators establish a model for predicting the efficacy of conversion therapy for the patients with unresectable liver metastases of colorectal cancer based on the detection of 5-hydroxymethylcytosine (5-hmC) in training group and validate the effectiveness of the model using a validation group.

NCT ID: NCT03676075 Recruiting - Colorectal Cancer Clinical Trials

A Multi-center Trial to Establish a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA

Start date: December 1, 2018
Phase:
Study type: Observational [Patient Registry]

In this study, the investigators establish a model for the early diagnosis of colorectal cancer based on the detection of 5-hydroxymethylcytosine (5-hmC) in training group and validate the effectiveness of the model using a validation group recruited from multiple centers.

NCT ID: NCT03668431 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Start date: October 15, 2018
Phase: Phase 2
Study type: Interventional

This research study is studying a combination of drugs as a possible treatment for metastatic colorectal cancer characterized by BRAF V600E mutation. The names of the study drugs involved in this study are: - Dabrafenib - Trametinib - PDR001